Cargando…

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolter, P, Stefan, C, Decallonne, B, Dumez, H, Bex, M, Carmeliet, P, Schöffski, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527784/
https://www.ncbi.nlm.nih.gov/pubmed/18665181
http://dx.doi.org/10.1038/sj.bjc.6604497
_version_ 1782158835764428800
author Wolter, P
Stefan, C
Decallonne, B
Dumez, H
Bex, M
Carmeliet, P
Schöffski, P
author_facet Wolter, P
Stefan, C
Decallonne, B
Dumez, H
Bex, M
Carmeliet, P
Schöffski, P
author_sort Wolter, P
collection PubMed
description Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational study with the aim of more accurately defining the incidence and severity of hypothyroidism in RCC or GIST patients receiving sunitinib. Thyroid function was assessed at baseline and on days 1 and 28 of each treatment cycle. Thyroid antibodies were assessed at baseline and during follow-up if abnormal thyroid function tests were recorded. Sixteen patients (27%) developed sub- or clinical hypothyroidism and required hormone replacement and 20 patients (34%) showed at least one elevated thyroid-stimulating hormone not requiring therapeutic intervention. Twenty patients (34%) did not develop any biochemical thyroid abnormality. Thus, sunitinib can induce (sub-) clinical hypothyroidism, warranting close monitoring of thyroid function. We propose a new algorithm for managing this side effect in clinical practise.
format Text
id pubmed-2527784
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-25277842009-09-11 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Wolter, P Stefan, C Decallonne, B Dumez, H Bex, M Carmeliet, P Schöffski, P Br J Cancer Clinical Study Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational study with the aim of more accurately defining the incidence and severity of hypothyroidism in RCC or GIST patients receiving sunitinib. Thyroid function was assessed at baseline and on days 1 and 28 of each treatment cycle. Thyroid antibodies were assessed at baseline and during follow-up if abnormal thyroid function tests were recorded. Sixteen patients (27%) developed sub- or clinical hypothyroidism and required hormone replacement and 20 patients (34%) showed at least one elevated thyroid-stimulating hormone not requiring therapeutic intervention. Twenty patients (34%) did not develop any biochemical thyroid abnormality. Thus, sunitinib can induce (sub-) clinical hypothyroidism, warranting close monitoring of thyroid function. We propose a new algorithm for managing this side effect in clinical practise. Nature Publishing Group 2008-08-05 2008-07-29 /pmc/articles/PMC2527784/ /pubmed/18665181 http://dx.doi.org/10.1038/sj.bjc.6604497 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Wolter, P
Stefan, C
Decallonne, B
Dumez, H
Bex, M
Carmeliet, P
Schöffski, P
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title_full The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title_fullStr The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title_full_unstemmed The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title_short The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
title_sort clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527784/
https://www.ncbi.nlm.nih.gov/pubmed/18665181
http://dx.doi.org/10.1038/sj.bjc.6604497
work_keys_str_mv AT wolterp theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT stefanc theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT decallonneb theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT dumezh theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT bexm theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT carmelietp theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT schoffskip theclinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT wolterp clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT stefanc clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT decallonneb clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT dumezh clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT bexm clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT carmelietp clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation
AT schoffskip clinicalimplicationsofsunitinibinducedhypothyroidismaprospectiveevaluation